Skip to main content
Equibles
RNAC logo

RNAC · Cartesian Therapeutics, Inc. · Metrics

Track RNAC — free

Use RNAC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RNAC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.20 -0.21 (-3.28%)
Russell 2000 member Rebalance outlook locked
Market Cap
$193.94M
Shares
30.26M
Volume · Oct 23 85.73K Avg daily vol (3M) 131.68K

RNAC metrics

82 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.18
Market cap
$193.94M

Price action

20 metrics
Price change (1W)
-2.6%
Price change (30D)
-20.7%
Price change (3M)
-19.1%
Price change (6M)
-8.0%
Price change (YTD)
-11.1%
Price change (1Y)
-28.7%
Trailing year
Price change (5Y)
—
52-week high
$10.59
52-week low
$5.84
Change from 52-week high
-39.5%
Change from 52-week low
+9.8%
Annualized volatility
82.8%
Annualized volatility (3M)
49.6%
Beta
1.5
RSI (14D)
35.8
Price vs SMA 50
-20.8%
Price vs SMA 200
-16.6%
Avg volume (3M)
132,527
Relative volume
0.7
Average dollar volume
$1.06M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
30.26M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
67.4×
reciprocal yield 1.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
131.5×
reciprocal yield 0.8%
P / book
—
FCF yield
-40.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-78.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
4.6×
reciprocal yield 21.7%
EV / revenue historical average (5Y)
9.8×
reciprocal yield 10.2%
EV / EBIT historical average (3Y)
7.6×
reciprocal yield 13.2%
EV / EBIT historical average (5Y)
7.6×
reciprocal yield 13.2%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-05-08

Profitability

9 metrics
Gross margin
—
Operating margin
-10,518.6%
Trailing 12 months
Net margin
-10,283.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$155.36M
Net income (TTM)
−$151.89M
Trailing 12 months
Diluted EPS (TTM)
$-5.84
FCF margin
-5,322.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.06
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-5.85
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-5.94
Operating cash flow per diluted share (TTM)
$-2.82
Free cash flow per diluted share (TTM)
$-2.90
Capital expenditures per diluted share (TTM)
$0.08
R&D per diluted share (TTM)
$2.51
Stock compensation per diluted share (TTM)
$0.34
Book value per share
$-4.85

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
-0.7%
Revenue (TTM)
$1.48M
Trailing 12 months
EPS growth YoY
-8.0%
Shares change YoY
+12.9%
Year over year · more shares
Revenue CAGR (3Y)
-70.7%
Revenue CAGR (5Y)
-30.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-47.7%
Debt / equity
—
Current ratio
7.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$78.61M
Quick ratio
7.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$94.75M
Latest balance sheet
Cash & equivalents
$147.61M
Total assets
$318.63M
Total debt
$52.85M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$76.53M
Capital expenditures (TTM)
$2.08M
R&D (TTM)
$68.39M
SG&A (TTM)
—
Stock compensation (TTM)
$9.24M
R&D / revenue
4,630.0%
Stock compensation / revenue
625.6%

Ownership (13F)

9 metrics
13F filers
95
13F filer change QoQ
+12
Institutional ownership
29.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
16.4%
Private-fund adviser ownership
15.9%
Active holders' share change QoQ
+17.0%
Holder tenure
7.2
Price vs estimated holder cost
+33.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.9%

Short interest

3 metrics
Short interest
6.1%
Latest settlement · 12.6 days to cover
Days to cover
12.6d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1453687 CUSIP 816212302 13F (30d) 12 filings 12 filers Visit website Investor relations